Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.
BioVie Inc. (NASDAQ: BIVI) generates news primarily through its clinical development programs in neurological and neurodegenerative disorders and advanced liver disease. Company announcements frequently highlight progress with its lead candidate bezisterim (NE3107) in Alzheimer’s disease, Parkinson’s disease and long COVID, as well as developments in its BIV201 program for complications of advanced liver cirrhosis.
Recent news releases have described milestones in the SUNRISE-PD Phase 2 trial in early Parkinson’s disease, including the use of a hybrid, decentralized design that allows participants to complete visits at home or in clinics, and the completion of enrollment in that study. BioVie also issues updates on scientific presentations at international conferences, where it has discussed bezisterim’s potential effects on biological aging markers, DNA methylation patterns, inflammatory gene expression, and metabolic and inflammatory biomarkers in Alzheimer’s disease.
In long COVID, BioVie’s news flow includes coverage of the ADDRESS-LC Phase 2 trial, which is enrolling adults with fatigue and cognitive impairment associated with long COVID and is fully funded by a U.S. Department of Defense grant. Press releases describe the trial’s enrichment strategy, objective cognitive endpoints, and the rationale for targeting neuroinflammation and insulin resistance in this condition.
BioVie also reports on capital markets and corporate events, such as underwritten public offerings of units consisting of common stock (or pre-funded warrants) and warrants, the listing of its warrants under the symbol BIVIW, and investor webinars featuring management discussing clinical data and program updates. Regulatory and governance news, including reverse stock split implementation, proxy statements, and board appointments, is disclosed through SEC filings and related communications.
Investors and observers following BIVI news can expect updates on clinical trial enrollment and topline data timing, scientific presentations, financing transactions, and corporate governance actions, all of which are documented in the company’s press releases and regulatory filings.
ORLANDO, FL / ACCESSWIRE / March 24, 2023 / RedChip Companies will feature BioVie Inc. (NASDAQ:BIVI) in upcoming interviews on The RedChip Money Report® airing on Bloomberg TV on March 25 at 7 p.m. Eastern Time (ET). The program reaches approximately 73 million households in the U.S. BioVie is a clinical-stage company focused on innovative drug therapies for neurological disorders and liver disease. Its key drug candidates include NE3107 for Alzheimer's and Parkinson's diseases, and BIV201 for liver cirrhosis, both under ongoing clinical evaluations. Watch the interviews at BioVie Interview Access.
BioVie Inc. (NASDAQ: BIVI) announced that data from its Phase 2 trial of NE3107 in Parkinson's Disease will be presented at the AD/PD 2023 conference in Gothenburg, Sweden, from March 28 to April 1, 2023. The oral presentation will discuss the Safety, Tolerability, and Efficacy of NE3107 in patients treated with levodopa/carbidopa. Additionally, a poster presentation will cover the pharmacokinetic profile of NE3107. The trial results indicated that NE3107 may improve motor control without causing adverse events. BioVie is also conducting a Phase 3 study for NE3107 in Alzheimer's disease and a Phase 2b study for BIV201 in patients with liver cirrhosis.
BioVie Inc. (NASDAQ: BIVI) is hosting a virtual event, BioVie Day, on March 23, 2023, at 10 a.m. Eastern Time, to discuss its research in neurological and liver diseases. The session will cover chronic inflammation's role in disease, updates on clinical programs for Alzheimer’s and Parkinson’s, and the company's regulatory and commercialization strategies.
BioVie is advancing its drug candidates, including NE3107 for Alzheimer’s and Parkinson’s, and BIV201 for liver cirrhosis, both of which are in critical phases of clinical trials. Investors are encouraged to register for the event to gain insights into the company’s future direction.
BioVie Inc. (NASDAQ: BIVI) announced a pause in patient enrollment for its Phase 2b clinical trial of BIV201, aimed at treating refractory ascites. Initial results from 15 patients showed a 34% reduction in ascites fluid after 28 days of treatment, significantly outperforming those receiving standard care. Notably, patients who completed treatment experienced a 53% reduction in ascites fluid, indicating the potential of BIV201 as a treatment option. The drug has received Orphan Drug and Fast Track designations from the FDA, and the company plans to discuss progressing to a pivotal Phase 3 trial.
BioVie Inc. (NASDAQ: BIVI) announced its management team's participation in the Oppenheimer 33rd Annual Healthcare Conference, scheduled for March 13-15, 2023. The virtual presentation will take place on March 15, 2023, at 12:40 PM ET, featuring one-on-one investor meetings. BioVie is focused on developing innovative drug therapies for neurological disorders, including Alzheimer's and Parkinson's diseases, and advanced liver disease. Their drug candidate NE3107 is undergoing pivotal trials for Alzheimer's, while BIV201 is in a Phase 2b study for liver cirrhosis. The company aims to improve patient outcomes with its groundbreaking therapies.
BioVie (NASDAQ: BIVI) has announced encouraging preliminary results from its Phase 2 trial of NE3107 for Parkinson's Disease (PD). Six out of 20 patients treated with NE3107 experienced a morning 'on state', compared to none in the placebo group (p=0.02). This state is crucial for PD patients as it indicates optimal motor function. Additionally, NE3107-treated patients showed a significant improvement in motor scores on the Unified Parkinson's Disease Rating Scale compared to those on levodopa alone. The company plans to initiate Phase 3 trials for NE3107, following favorable Phase 2 results.
BioVie Inc. (NASDAQ: BIVI) announced the successful completion of patient enrollment for its NM101 trial, evaluating NE3107 in Alzheimer’s patients, achieving a revised target of 400 patients. The trial is a pivotal Phase 3 study aimed at assessing cognition and function in mild to moderate Alzheimer’s disease patients. Top line results are anticipated in October 2023. The study protocol adapted to increased interest, allowing for enhanced statistical power. Previous Phase 2 results indicated improved cognition with NE3107 treatment. The company aims to address neuroinflammation and insulin resistance related to neurodegenerative diseases.
BioVie (NASDAQ: BIVI) has announced its upcoming BioVie Day on March 23, 2023, at 10 a.m. EST, where it will present a comprehensive overview of recent clinical trial data on its treatments for Alzheimer's, Parkinson's, and liver diseases. This event aims to summarize progress, discuss new clinical trials, and outline plans for regulatory submissions. Notable achievements include the promising Phase 2 results for NE3107 in Alzheimer's and Parkinson's, showing significant cognitive and motor control improvements. Additionally, the liver disease candidate BIV201 holds FDA Fast Track status. More details will be shared as the date approaches.
BioVie Inc. (NASDAQ: BIVI) will be featured in an interview on The RedChip Money Report on Bloomberg TV on December 31, 2022, at 7 p.m. ET. CEO Cuong Do will discuss positive Phase 2 clinical trial data for Alzheimer's and Parkinson's diseases, and plans for potential FDA approval in 2024. BioVie is developing innovative therapies for neurodegenerative disorders and liver disease, with key studies underway for its drug candidates NE3107 and BIV201. The interview will be accessible online and aims to inform investors about the company’s progress.
BioVie Inc. (NASDAQ: BIVI) recently reported significant advancements with its drug candidate NE3107 for treating Parkinson's disease (PD) and Alzheimer's disease (AD). In a trial, PD patients using NE3107 experienced a meaningful increase in motor control after 28 days. Additional data indicated that NE3107 improved cognition in mild cognitive impairment and mild AD patients. Notably, NE3107 reduced biomarkers of aging-related disease by approximately 3.3 years after 3 months of treatment. The company is moving toward Phase 3 trials based on promising results.
FAQ
What is the current stock price of Biovie (BIVI)?
What is the market cap of Biovie (BIVI)?
